Point of Sale Voucher Program

The Point of Sale (POS) voucher program is available for certain GSK medications and works in real time at participating pharmacies for patients insured through commercial health plans. The program offers eligible patients medications at a reduced cost. This program is not offered for residents of Massachusetts or for patients enrolled in or eligible for Medicare, and patients enrolled in Medicaid, or any similar state or federal program.

This Program does not constitute health insurance. The Point of Sale Voucher Program is only available for eligible patients taking certain GSK medications. The current Point of Sale Voucher offers and their availability are defined below:


Brands offering Point of Sale Vouchers for eligible patients insured through commercial health plans who are NOT subject to certain formulary limitations (such as a prior authorization, step-edit, or NDC block).

ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder)
Prescribing Information Including Boxed Warning

ANORO ELLIPTA Point of Sale Voucher Offer is only available for commercially insured patients:

  • With a valid prescription for ANORO ELLIPTA
  • New to ANORO ELLIPTA therapy as of November 13, 2018 (Patients who started taking ANORO prior to November 13, 2018 are NOT eligible)
  • Current program will end for all patients on December 31, 2020

BREO ELLIPTA (fluticasone furoate and vilanterol inhalation powder)
Prescribing Information

BREO ELLIPTA Point of Sale Voucher Offer is only available for commercially insured patients:

  • With a valid prescription for BREO ELLIPTA
  • New to BREO ELLIPTA therapy as of July 18, 2017 (Patients who started taking BREO prior to July 18, 2017 are NOT eligible)
  • Current program will end for all patients on August 31, 2019

TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol inhalation powder)
Prescribing Information

TRELEGY ELLIPTA Point of Sale Voucher Offer is only available for commercially insured patients:

  • With a valid prescription for TRELEGY ELLIPTA
  • Who start taking TRELEGY ELLIPTA prior to December 31, 2019
  • Current program will end December 31, 2020


Brands offering Point of Sale Vouchers for eligible patients insured through commercial health plans who ARE subject to certain formulary limitations (such as an NDC block)

TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol inhalation powder)
Prescribing Information

TRELEGY ELLIPTA Point of Sale Voucher Offer is only available for commercially insured patients:

  • With a valid prescription for TRELEGY ELLIPTA
  • Who start taking TRELEGY ELLIPTA prior to December 31, 2018
  • Current program will end December 31, 2019

How does this point of sale voucher program work?

Once the pharmacist submits the prescription, the automated voucher will be applied for eligible patients. There is no need to provide additional information or a paper coupon or free trial offer to the pharmacist.

Customer Support:

For questions or more information about this program please click this link to access the GSK Response Center site where you find contact information and submit questions online.